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Dear Editor,
On behalf of my co-authors please consider our revised article submission entitled “IgA binds to the AD-
2 epitope of glycoprotein B and neutralizes Human Cytomegalovirus “  to your journal Immunology. We 
thank you for the opportunity t  revise the article. Together, we have now modified and revised the article 
based on the two reviewer’s comments and feel that it has significantly improved as a result. The reviewer 
comments were positive, thoughtful and scientifically sound and have really helped improving the article. 
We thank the reviewers for their careful analysis of the original submission. During revision we found 
some additional errors or omissions in figure legends that have also been corrected.
A point by point outline and rebuttal of reviewer comments is shown below and indicates where we have 
made major changes and the minor modifications requested. We also justify where we feel the reviewer 
changes were not necessary.
We hope that you find that our article has improved and that you feel it is appropriate for publication in 
the journal.
Yours sincerely,
Gary R McLean, PhD
Point by point outline of changes made: our comments and changes are highlighted in blue text.
Reviewer 1
Introduction. “hyperimmune globulin preparations have been successfully used for preventing 
congenital HCMV infection [9]”: the authors should take into account that the only randomized 
controlled trial did not find a significant effect of hyperimmune globulin in preventing congenital 
infection (Revello et al., NEJM 2014).
We reworded this sentence to reflect mixed success of this approach and added 2 new supporting 
references 10 and 11. Nigro et al 2005 and Revello et al 2014.
ELISA.
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More details should be presented for the ELISA method. Was a negative control antigen (or no antigen) 
used and result subtracted from the reactivity with antigen? It is not clear if coating with anti-human 
kappa and lambda chains was used for determination of kappa and lambda light chain usage.
We have clarified these details in the methods section and figure legends where appropriate to more 
accurately describe the ELISA method and avoid confusion. We have not used a negative control antigen 
in any experiments since we feel that background reactivity should be shown and is in fact minimal. 
Furthermore, all cohorts contained several negative samples which are demonstrated in supplementary 
figures and are used to define the cut off values critical for the analysis of data. The recombinant Ab 
experiments also used unrelated isotype controls that demonstrated very low binding. Therefore we are 
confident that all positive results reflect specific binding.
Samples were incubated overnight. Is this because classical 1-2h incubation yielded low reactivity?
AD-2 peptide was directly coated. Is it possible that direct coating could alter the peptide conformation 
and reduce the antibody binding? Using biotinylated peptides on streptavidin-coated plates might 
reduce this (potential) issue.
This incubation time has been shown previously (McLean et al 2005; ref 22) to improve signals of AD-2 
binding and is required for reaching equilibrium. Whilst shorter incubations also result in specific binding, 
more consistent results are achieved with this longer protocol and results in reduced non-specific 
interactions, particularly with polyclonal preparations. We have also shown previously that coating plates 
directly with the AD-2 peptide has little effect on ability of Abs to bind in this format. Even for mAb binding, 
where structural analyses have demonstrated the critical presence of the terminal Y residue in AD-2, 
directly coated peptides still work effectively in combination with the longer incubation time to allow for 
equilibrium, specificity and robust binding.
In the figures showing the OD results, the line showing the cutoff value could be represented. In Figure 5 
the symbols for kappa and lambda do not appear in the axis legend.
Thank you for pointing this omission out. We have added cut off values in Figure 1A and 1B, Figure 4A 
and Figure 5A. Furthermore, all cut off values are described and shown in SFig 1 within data tables and 
also for breast milk in SFig 3. We have also corrected Fig 5 symbols that must have appeared during PDF 
conversion of the original file during the submission process.
Neutralization.
The authors should report the virus strain used for the neutralization assay. Neutralization was tested on 
fibroblast cells only, but could be also tested on other cell types (epithelial or endothelial) in which the 
virus enter with different mechanism, to verify whether the efficacy of IgA is similar.
The improvement of neutralizing efficacy of 8F9 when expressed as IgA1 is clear but low (less than 10 
fold), thus maybe not biologically relevant
We have now added the details of the virus strains used within methods section and figure legends where 
appropriate. We have also performed the additional experiment using epithelial cells as requested. This 
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experiment was done at UCL and required addition of a new author, Megan R McIntosh 
(m.mcintosh@ucl.ac.uk), in the middle of the author list. The method section, results text and figure 
legends have been updated to reflect this additional data. We added a new figure Fig 7C demonstrating 
the results achieved which support data obtained with fibroblast cells. We thank the reviewer for this 
insightful addition that was important to perform.
We agree that the IgA neutralization effects may not be biologically relevant but our aim was to simply 
demonstrate that IgA binding AD-2 could neutralize HCMV. We have achieved this using novel 
recombinant Abs that, to our knowledge, no one else has attempted previously. Extrapolation of the 
meaning of these data to biological situations will require more careful future analyses using samples 
containing a mixture of Abs.
Correlation analysis.
The correlation analysis performed is not correct. First the authors should test whether the correlation is 
significant, providing the p value. Then the “r” (and not r<sup>2</sup>) value should be calculated. I 
suggest to calculate the Spearman correlation (which does not assume a linear relationship between the 
two variables) instead of Pearson’s. However, the correlations shown appear very weak and the relevant 
figures could be removed or presented in the supplementary material.
We thank the reviewer for pointing this out and have corrected these analyses. We fixed these in Figures 
2, 4B and 5B plus modified text explanations in methods, results and figure legends. We show p values 
and Spearman correlation. In fact, with these new correct analyses performed, the correlations now look 
improved and therefore we have left these as parts of main figures within the text as it adds another level 
of analysis not shown by individual dot plots. Representation of these data as scatterplot correlations 
allowed us to compare individual IgG and IgA responses to gB and AD-2 together. We therefore decided 
against removal or relegation of these to supplementary material.
IgG and IgA responses to HCMV gB and AD-2 in recombinant gB vaccine recipients.
“The gB/MF59 vaccine boosted gB binding Abs in seropositive recipients particularly in the IgA 
responses…”
I would say “only” instead of “particularly”, since no significant increase is observed in the IgG 
responses.
“IgG and IgA responses to AD-2 were similarly boosted…” This statement is misleading, because IgG and 
IgA to gB were NOT boosted in the general population analysed, since no significant increase was 
observed. However, they were boosted in those subjects with pre-existing AD-2 responses (suppl Fig 
2A), and this observation is interesting. These sentences should be revised in order to underline that AD-
2 responses do not develop in all subjects and vaccination can boost these responses only in 
seropositive subjects that have already developed AD-2 responses after natural infection. Conversely, 
vaccination with the current gB formulation does not elicit de novo AD-2 response in seronegative or 
seropositive subjects.
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Finally, it is not clear what the authors mean with “mixed but significant IgA responses”.
The reviewer is correct that many of these statements were unclear, misleading or not supported. We 
have therefore revised all of these occurrences to accurately reflect the findings of these studies. The 
vaccine responses are complex, particularly when looking at epitope specific findings in different groups 
that may or may not have prior seropositivity – this is confounded even more by the AD-2 responses that 
only occur in a subset of seropositive individuals. We hope that the revised text is more accurate of what 
the data actually shows.
Binding to cell-associated gB.
I am wondering why only the N-terminus was expressed on the cells and not the whole gB. Did the 
authors verify that expression of the N-terminus alone preserve the epitope conformation of the whole 
cell-associated gB?
This is a good point raised by the reviewer. This construct and format of antigen was also previously 
published in the original 2005 paper describing the human AD-2 mAbs (McLean et al, 2005; ref 22). We 
justified this previously due to the large size and difficulty expressing structurally intact full-length gB. We 
had chosen the N-terminus containing the AD-2 epitope to display the epitope differently and found that 
lower affinity Abs prefer AD-2 arrayed in this manner. We suspected that IgA might prefer this format of 
AD-2 also. This region of gB is disordered in the solved gB structures and therefore not included so we are 
unclear if it resembles gB or not. We have also added in the methods the exact region that is referred to 
as gB-NT and noted it only contains AD-2 and surrounding residues (amino acids 28-100) which do not 
contain any other known gB epitopes.
Reviewer 2
The paper would benefit from more precise language, as it was challenging as a reader to connect the 
data to the written results. This Overall, the findings put forth are interesting and novel and investigate a 
highly relevant question to researchers in CMV and vaccine development.
We have checked the paper throughout and have modified text to be more precise.
Overall, this study would benefit from briefly introducing the importance of IgA antibodies and how 
protection by IgA in the relevant compartments (sera, saliva, and breast milk) might be different from 
that of IgG.
Agreed, we have added and new section and reference (ref 16) to the introduction describing the 
importance of IgA.
In the abstract, the concept of generating  "de novo" responses in seropositive individuals through 
vaccination - how is this defined?
Page 4 of 39Immunology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
We have defined this better in the abstract that we refer to new AD-2 responders in seronegative group 
here.
This manuscript investigates the use of kappa and lambda light chains in anti-gB AD-2 Ig responses. Why 
was this investigated? What is the significance of kappa or lambda usage in protection or Ig function? 
The potential connection to host restriction of “immune responses to conserved epitopes” is alluded to 
in the Discussion, but it would help readers for this idea to be introduced in Introduction.
It was previously suspected that all human Abs to AD-2 are restricted to using kappa light chains. We also 
knew from prior mAb structural studies of 8F9 that the light chain makes important contacts with AD-2 
(Thompson et al, 2008 EMBOJ). Therefore we took the opportunity in these studies to investigate this 
concept further and attempt to link light chain to significance of forming Abs to AD-2 in various human 
samples and cohorts. We have therefore introduced the idea to readers in the introduction to outline this 
area of study. We feel that the Ab light chain is often overlooked and in this situation of restricted nature 
of Ab formation to a critical HCMV epitope, it goes some way to explaining why AD-2 Abs are less frequent 
than others.
Overall, this reviewer would advise careful reading of the manuscript to remove the words “clearly,” 
“significantly,” and related adverbs when describing trends that are not statistically significant.
We agree with the reviewer comment and have corrected the text throughout to remove these inaccurate 
words. The text now reads more simply and carefully describes trends shown in these data.
Page 3, Line 15: The statement “Recombinant gB vaccination has displayed limited efficacy through 
reductions in primary maternal infection and prevention of congenital infections” is incorrect as written. 
The paper cited for this (Pass et al., 2009 NEJM) found that CMV-seronegative postpartum women 
vaccinated with gB/MF59 had a lower risk of acquiring primary CMV infection in postpartum women. 
This study evaluated neither pregnant mothers nor congenital transmission, and to this reviewer’s 
knowledge, the gB/MF59 vaccine has not been shown to reduce congenital transmission in any other 
studies to-date. Moreover, the gB/MF59 vaccine was 50% efficacious in the Pass et al study, which 
would be considered moderate level efficacy and should be noted as such.
Thank you for flagging this issue and we have now corrected both of these instances in the introduction 
to reflect the results from the study.
Page 3, Line 49: The concluding sentence extends beyond the author’s findings in this study.
We changed the text to tone down the conclusion made.
Page 4, Line 23: Indicate the timepoint at which gB/MF59 samples were assayed (months post-
vaccination).
Page 4, Line 52: Please list the concentrations for the coating antibodies and antigens.
Page 4, Line 56: Please list virus strains used in neutralization assays here and/or in the figure legend.
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We added this information to the method section in the appropriate places and if necessary to the 
figure legend.
Supplementary Fig. 4: There appear to be errors in the uploaded pdf. The x and y axis have boxes in 
place of labels.
As also noted by reviewer 1, this must have arisen due to PDF conversion during submission. We will 
make sure that this does not occur during resubmission.
Page 7, Lines 6-7: The phrase “saliva results (Fig. 1B) match those observed with serum (Fig. 1A)” could 
be written more clearly. Does the author mean that the trends observed, with higher IgG responses than 
IgA responses against gB and gB AD-2, are similar in saliva and sera? 
Agreed, we have corrected this in the results text to clarify the trends are similar.
•       Page 7, Line 48: “IgG and IgA responses to AD-2 were similarly boosted” is not supported by the 
data, as this is not a statistically significant finding.
We corrected this previously as it was also indicated by reviewer 1.
•       Page 7, Line 52-57: This section is difficult to understand. Please clarify how individuals were 
stratified into “AD-2 responders and non-responders.” Please add figure references as needed here, and 
clarify clearly which responses are being compared against one another.
We have added an explanation to the text and also within the legend of supplementary Figure 2 where 
these data re shown. It should be much more obvious now that only individuals with one positive AD-2 
response (day 0 or day 5 of matched samples) were analysed. This has the effect of eliminating all the 
confounding AD-2 non responders from the statistical analysis and therefore allowing demonstration of 
significant differences.
•       Figures
o       Fig. 1: The negative threshold cut-off for this assay is determined using the sera binding responses 
of CMV-seronegative samples (Supp. Fig. 1), but there should be two negative thresholds: one for sera 
and one for saliva. Please include the CMV-seronegative sample saliva binding threshold, and indicate 
both thresholds on Fig. 1.
We have done this in the necessary figures as outlined for reviewer 1.
o       Figures 2 and 4: What are the p values for these correlations? Were multiple comparison 
corrections applied? Also, Figures 1 and 2 should have the same x and y axis ranges, since these are the 
same data, right?
We have also corrected this statistical analysis as outlined for reviewer 1 showing p values and Spearman 
correlation. We have kept the axes ranges as consistent as possible to display all data points. Importantly 
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these are consistent between serum and saliva for Fig 2A and Fig 2B to demonstrate and allow direct 
comparisons of responses.
o       Fig. 2A saliva: The x axis should be consistent across all dilutions.
o       Fig. 4A: Please indicate the positive/negative threshold cut-off on this figure.
These changes and additions have been made in both figures.
Minor comments:
•       Page 1, Line 15: “Foetuses developing in utero” can be changed to just “fetuses.”
Agreed, this sentence has been changed.
•       Page 1, Line 48: “Antigenic determinants” should be “antigenic domains.”
This word determinant is frequently used in the literature to describe the AD regions of HCMV gB. We left 
this as it is. Domain is often referred to as a larger structural region rather than epitope.
•       Page 3, Line 42: In reference to the “matched human serum and saliva samples,” please clarify 
what matching was performed in methods.
We added words “each” and “both” to sample collection in the methods to document that each volunteer 
donated both serum and saliva – therefore matched.
•       Page 6, Lines 56-59: Run-on sentence.
Added next to correct this.
•       Supplementary figures:
o       Supp. Fig. 1: Please clarify how the positive-negative cutoff was determined (ie. Was the cut-off 
defined as the highest binding magnitude of one CMV-seronegative sample? Or is this based on an 
average of the binding responses of the CMV-seronegative samples per antigen? The method to 
determine the cut-off is unclear from the figure).
We added text to the SFig 1 legend to define how these values were obtained – it is the mean + 2SD of 
all 4 samples in replicate assays.
SFig 5A - there appears to be a compensation issue with the flow cytometry of the N50 cells - can this be 
corrected?
It is not compensation here which is spillover from one fluorescent channel to another – as we only work 
with one fluorescent marker so there is no issue. The reviewer may be referring to the different FSC and 
SSC profiles of parental NS0 v NS0 gBNT which has been drug selected and cloned – the cell populations 
therefore display different parameters of size and granularity as shown in the dot plots. We don’t feel that 
these change the Ab binding results shown – particularly as NS0 are negative control.
Page 7 of 39 Immunology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
IgA binds to the AD-2 epitope of glycoprotein B and neutralizes Human Cytomegalovirus
Saima Siddiqui1, Sarah Hackl1, Hamid Ghoddusi2, Megan R. McIntosh3, Ariane C. Gomes3, Joshua 
Ho3, Matthew B. Reeves3, Gary R. Mclean1,4,*
1Cellular and Molecular Immunology Research Centre and 2Microbiology Research Unit, London Metropolitan 
University, 3Institute for Immunity and Transplantation, University College London, 4National Heart and Lung 
Institute, Imperial College London, London, UK
*Corresponding author: CMIRC, London Metropolitan University, 166-220 Holloway Road, London UK N7 8DB 
g.mclean@londonmet.ac.uk
Abstract
Human cytomegalovirus (HCMV) is a ubiquitous pathogen that is potentially pathogenic in 
immunosuppressed individuals and pregnant females during primary infection. The HCMV envelope 
glycoprotein B (gB) facilitates viral entry into all cell types and induces a potent immune response. AD-
2 epitope is a highly conserved linear neutralising epitope of gB and a critical target for antibodies, 
however, only 50% of seropositive individuals make IgG antibodies to this site and IgA responses have 
not been fully investigated. This study aimed to compare IgG and IgA responses against gB and the 
AD-2 epitope in naturally exposed individuals and those receiving a recombinant gB/MF59 adjuvant 
vaccine. Thus, vaccination of seropositive individuals improved pre-existing gB specific IgA and IgG 
levels and induced de novo gB specific IgA and IgG responses in seronegative recipients. Pre-existing 
AD-2 IgG and IgA responses were boosted with vaccination but de novo synthesis wasAD-2 responses 
were not detected. Naturally exposed individuals had dominant IgG responses towards gB and AD-2 
compared with weaker and variable IgA responses, although a significant IgA binding response to AD-2 
was observed within human breast milk samples. All antibodies binding AD-2 contained kappa light 
chains whereas balanced kappa/lambda light chain usage was found for those binding to gB.  V-region 
matched AD-2 specific recombinant IgG and IgA bound both to gB and AD-2 and neutralized HCMV 
infection in vitro. Overall, these results indicate that although human IgG responses dominate, IgA 
class antibodies against AD-2 are a significant component of human milk which may function to 
protect neonates from HCMV.
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Introduction
Human cytomegalovirus (HCMV) is a ubiquitous pathogen that affects approximately 85% of the global 
human population [1]. HCMV infection is resolved naturally in healthy individuals due to a rigorous 
immune response but this opportunistic pathogen remains a substantial cause of morbidity and 
occasional mortality in immunocompromised patients such as transplant recipients [2], AIDS patients 
[3] and in foetuses developing in utero [4, 5]. Consequently, this clinical burden has led to the 
application of antiviral therapies [6], antibody-based treatments [7] and a high priority placed on 
vaccine development for HCMV intervention [8]. Limitations of these therapies and prophylactics has 
necessitated a deeper understanding of the HCMV life cycle, viral structural determinants and host 
immune correlates of protection. This in turn has led to the development in recent years of numerous 
monoclonal antibodies (mAbs) and novel vaccine candidates for HCMV. 
Although hyperimmune globulin preparations have been successfully used for preventingshown 
mixed success in the prevention of congenital HCMV infection [9, 10] [11] and HCMV disease in solid 
organ transplantation [12], the increasing use of mAbs as therapeutics and prophylactics for human 
diseases [13] has spurred interest in the development of antiviral mAbs, including for HCMV [7]. 
Numerous mAbs are under preclinical development and target diverse structural components of the 
virus that are required for entry into cells. The major viral targets of mAbs and host humoral immunity 
are the glycoprotein B (gB) and the pentamer complex consisting of gH, gL, pUL128, pUL130 and 
pUL131A. Abs to these viral components are known to block infection of fibroblasts, epithelial cells, 
endothelial cells, macrophages and dendritic cells [14, 15]. Most mAbs studied are of the IgG isotype 
despite increasing evidence of the importance of IgA, particularly at mucosal surfaces [16]. Humans 
have two subclasses of IgA, with serum consisting of 90% of IgA1 and 10% IgA2 whereas in mucosal 
samples such as saliva and breast milk, the ratio is closer to 40:60 [16]. Furthermore, multiple 
molecular forms of IgA exist. In human serum IgA is predominantly monomeric whilst the mucosal 
secretory IgA (sIgA) is dimeric. It is predicted that IgA mAbs will be used more frequently in the future, 
and rival the therapeutic and prophylactic uses of IgG.
 
HCMV gB is a highly conserved glycoprotein among the herpesvirus family and plays a critical role in 
infectivity and cell-to-cell spread being the viral determinant critical for membrane fusion during entry 
[17]. Based on this critical role of gB in facilitating virus entry and being a well described immune 
system target, gB is a promising candidate for development of vaccines and Ab mediated therapies. 
Five antigenic determinants or epitopes (termed AD-1, AD-2, AD-3, AD-4, AD-5) located on gB have 
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been described [18]. The conformational AD-1 epitope was originally described as the major epitope 
[19], inducing production of IgG Abs in all infected individuals, however not all of the AD-1 epitope 
binding Abs are neutralizing [20]. Conversely, only 50% of seropositive individuals are capable of 
generating AD-2 specific Abs in spite of their potent neutralizing capability [21] and all human mAbs 
identified to this epitope are of the IgG subclass and have been shown to consist of kappa light-chains 
[18, 22, 23].The use of kappa light-chains is thought to restrict binding properties of human Abs to 
simpler epitope structures like AD-2 [24]. More recently, the AD-4 and AD-5 epitopes, which are 
conserved, immunogenic and induce potent neutralizing Abs, have been identified on gB [18]. The AD-
3 epitope was identified within the gB cytoplasmic domain and is a target of non-neutralizing Abs [18]. 
Thus, knowledge of gB epitope-based Abs has increased in recent years and coupled with the 
development of recombinant gB as a subunit vaccine [25] demonstrates its importance. 
At present, there is no licensed vaccine for HCMV, however, the recombinant gB subunit vaccine has 
been evaluated extensively in recent years through numerous clinical trials. Studies have 
demonstrated immunogenicity and safety, including the boosting of pre-existing immunity in those 
already infected with HCMV [26-30].  Recombinant gB vaccination has displayed limited partial efficacy 
through reductions in primary maternal infection, and prevention ofwhich would likely reduce the 
incidence of congenital infections [31], and was effective at reducing viremia when administered to 
kidney and liver transplant patients – particularly in seronegative vaccine recipients [32].  Despite 
these encouraging clinical trials where 50% vaccine efficacy was observed, the mechanistic correlate 
of protection for the gB vaccine remains elusive. Studies of sera taken from HCMV seronegative 
recipients of the gB vaccine demonstrated limited evidence of neutralising antibodies [33, 34] 
although in the transplant study, challenge of vaccinees with an organ from a HCMV seropositive 
donor did reveal a rapid accumulation of gB-specific neutralising antibodies post-transplant in some 
patients. In contrast, individuals naturally infected with HCMV do generate neutralising antibody 
responses directed against epitopes within gB including AD-2. Interestingly, two separate studies have 
suggested that AD-2 responses in naturally infected individuals are an important correlate of 
protection [35, 36] and, vaccination with gB will boost this response in the 50% of individuals who 
have generated it in response to prior natural infection [37].  
 
Much of these prior studies have focused on the IgG response to gB and thus not fully assessing the 
entire repertoire of antibody responses to HCMV and vaccination. In this study, we have investigated 
the contribution of IgA alongside IgG Abs to gB and AD-2 generated by vaccination with recombinant 
gB and in healthy adults naturally exposed to HCMV. We report data obtained for serum IgG and IgA 
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responses to gB and AD-2 in gB/MF59 adjuvant vaccine recipients, matched human serum and saliva 
samples from individuals naturally exposed to HCMV, human breast milk samples and recombinant 
Abs specific for AD-2 formatted as human IgA or IgG. Our data indicate that whilst human IgG 
responses to gB and AD-2 predominate, substantial IgA responses were detected, particularly in breast 
milk., The demonstration that recombinant monoclonal IgA antibodies directed against AD-2 can 
neutralise HCMV infection in vitro argues that and IgA antibodies should be considered anothers a 
critical component of protective immunity to HCMV via AD-2.
Materials and methods
Antigens
The following HCMV specific antigens were used: gB recombinant protein, stock concentration 
0.8mg/ml, also used as the vaccine immunogen, provided by Sanofi Pasteur (Marcy, France) ; AD-2 is 
a short linear peptide made by solid-phase synthesis, stock concentration 1mg/ml, sequence 
SHRANETIYNTTLKYGDKL (minimal epitope shown bold) was synthesised and purchased from Alta 
Biosciences, UK.
Human samples collection, processing and storage
Human serum samples were obtained from a prior vaccine trial of recombinant gB from HCMV and 
MF59 adjuvant trial, performed on a group of solid organ transplant patients (NCT00299260) enrolled 
in a phase 2 randomized and double-blinded placebo-controlled study [32]. Samples were obtained 
from placebo or vaccinated volunteers at day 0 (baseline and first dose) and day 56 (1 month after 
second dose), blinded and were stored at -80°C until use.
Twenty-four healthy adult volunteer participants each donated both blood and saliva samples for 
matching purposes. Blood samples (5 ml) were collected in sterile tubes (without anticoagulant) and 
then left to clot. The samples were centrifuged at room temperature at 1300 rpm for 15 minutes and 
the serum fraction was separated from the clot. Serum was stored at −80°C prior to analysis. 
Volunteers also donated 2ml of saliva which was centrifuged at 10,000 rpm for 10 minutes at 4oC to 
remove cells and debris. The supernatant was collected and stored at -80oC prior to analysis. 
Participants were anonymised by coding the samples provided, therefore maintaining patient 
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confidentiality, safety and respect. Exclusion criteria included: volunteers suffering from any acute or 
chronic disease; age less than 18 years and pregnancy. The study was approved by the Research Ethics 
Committee of the School of Human Sciences of London Metropolitan University.
Fourteen human breast milk samples, originally collected from milk bank at Queen Charlotte's and 
Chelsea Hospital, Imperial College Healthcare NHS Trust, were kindly provided by the Microbiology 
Research Unit of London Metropolitan University. Each sample was vortexed briefly to dissolve fats 
and divided into four aliquots and stored at -80o C before analysis. 
ELISA
ELISA was performed as described earlier [22, 35] with the modification that coating with antigens to 
determine specific binding (AD-2 peptides or recombinant gB) or capture antibodies to determine 
levels of IgG and IgA, (anti-human kappa and anti-human lambda) diluted in PBS was performed 
overnight at 4°C. Antigens and capture antibodies were coated at a final concentration of 1g/ml. In 
all cases,and blocking was performed with 5% non-fat dry milk in PBS containing 0.1% Tween 20 (PBST 
milk) at 37°C for 2 hours. Samples diluted in PBST milk were added and plates were incubated 
overnight at 4°C. Peroxidase-labelled secondary Abs to human IgG, human IgA, human kappa and 
human lambda chains (Southern Biotechnology Associates, Alabama USA) were diluted in PBST milk 
and added to plates which were incubated at 37°C for 2 hours. Colour was developed following the 
addition of 3,3',5,5'-Tetramethylbenzidine (TMB, ThermoFisher) and stopped with 0.1M HCl. Washing 
was performed between steps using Skatron SkanWasher3000 and the optical density at 450nm was 
determined using an OMEGA plate reader (BMG Labtech). 
Human recombinant monoclonal antibodies
8F9, QG1 and FA9 are three human monoclonal IgG which bind to the AD-2 epitope of gB [22]. The L 
and H chain V regions cDNA of each were inserted into the human Ig expression vectors, pLC-huC, 
pHC-huC1 and pHC-huC1 expression vectors [38], for expression as human IgA1 and human IgG1 
monoclonal antibodies. L-chain and H-chain plasmids containing 8F9, QG1 and FA9 cDNA were 
propagated in E.coli after transformation and selection from LB-ampicillin plates, where single 
colonies were chosen and grown overnight at 37oC. Plasmids were isolated from bacterial cultures 
using Qiagen plasmid kits. Restriction digest was performed to confirm the plasmid integrity followed 
by Sanger sequencing to confirm correct Ab V regions. Plasmid concentrations were determined by 
Nanodrop UV spectrophotometry. 
Transient transfection of HEK 293 cells
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HEK 293 cells were seeded in a 6 well plate at 6.25 x 105 cells per well in 2 ml of Dulbecco’s modified 
Eagle’s medium (DMEM, Invitrogen) supplemented with 2% penicillin streptomycin (Invitrogen) and 
10% FCS (Invitrogen) the day before transfection. On the day of transfection, media was replaced with 
0.5 ml of OptiMEM medium. For each well of cells, 5 µl of Lipofectamine 3000 reagent was diluted 
into 125 µl of Opti-MEM TM medium and gently mixed. 5 µg of plasmid DNA (equal amounts of pLC 
and pHC) was diluted in Opti-MEM TM medium including 5 µl of P3000 reagent and mixed well. Diluted 
Lipofectamine 3000 reagent was combined with each tube of diluted DNA (1:1 ratio) and incubated at 
room temperature for 10-15 minutes to form DNA-Lipofectamine 3000 reagent complexes. After 
incubation, the complexes were added to each well containing cells and gently mixed by rocking the 
plate back and forth. After 4-5 hours incubation, DMEM-FCS was added and cells were incubated at 
37oC at 5% CO2 concentration for 4 to 5 days with media harvested and added each day. Supernatants 
were verified for monoclonal antibody expression by ELISA prior to further experiments. 
HCMV neutralization assays
HFFs (human foreskin fibroblasts) were seeded in 96 well cell culture plate and a confluent monolayer 
was allowed to form. Virus stocks ( TCID50 of 5.44x10ˆ6/mL of high passage Merlin strain) were diluted 
and added to infect the cells at a MOI of 1. Next, 100µl of each mAb (10µg/ml) was mixed with virus 
in triplicate, titrated and incubated for 30 minutes at 37oC. The antibody-virus mixture was then added 
to HFFs and incubated for one hour at 37˚C. The inoculum was removed and growth medium was 
added and incubated overnight at 37oC before the cells were fixed with cold, 100% ethanol (-20oC) for 
30 minutes, washed three times with PBS and stained for IE gene expression using anti-IE (Millipore; 
1:1000) for 1 hour at room temperature. Unbound antibody was removed by washing three times 
with PBS and reaction wells were stained with goat anti-mouse Alexa Fluor 568 nm (Life Technologies; 
1:2000) for 1 hour at room temperature. Nuclei were counterstained with 4′,6-diamidino-2-
phenylindole (DAPI). Unbound antibody was removed by washing three times with PBS and 
percentage infection was enumerated by immunofluorescence imaging using Hermes WiScan 
instruments. A similar method was employed using human retinal pigment epithelial cells (ARPE-19) 
as the target of infection. Here we pre-mixed IgA1 mAbs (diluted 1:3) with the an epithelial-tropic 
strain of HCMV (TB40/e) before following the procedure described above for HFFs.
Flow cytometry analysis
Mouse myeloma NS0 cells and engineered NS0 cells stably expressing the N-terminus of gB (residues 
28-100) containing the AD-2 epitope on their surface as described [22] were suspended at ~106/ml in 
PBS containing 0.5% FCS (FACS buffer) and then incubated with Abs for 30 min on ice. Following 
incubation, the cells were washed with ice-cold FACS buffer and then stained with diluted anti-human 
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к-chain FITC conjugate (Southern Biotechnology Associates) for 30 min on ice in dark. Fluorescence 
was analyzed using a Guava 8HT cytometer and the data was analysed using FCS Express (De Novo 
software).
Statistical Analyses
The analysis of data obtained was performed using Graph Pad Prism software. Data was first evaluated 
for normal distribution to ascertain which statistical tests should be applied. Statistical differences 
between the mean OD values of antibodies at each dilution was obtained from Mann-Whitney test 
(ns, not significant; * P < 0.05; **P < 0.005; *** P < 0.001, ****P < 0.0001 ). Correlations were assessed 
by Pearson’s Spearman’s correlation and the rR2 values and p values were stated.
Results
IgG and IgA responses to HCMV gB and AD-2 in HCMV seropositive volunteers
Serum and saliva samples were obtained from 24 healthy adult volunteers and screened for binding 
levels of IgG and IgA to recombinant gB and the AD-2 epitope (Fig 1). Four samples were found to be 
negative as defined by lack of serum IgG to gB when diluted 1:100 and these samples were used to 
define the positive-negative cut-off values for each Ab isotype binding to gB and AD-2 (Supplementary 
Figure 1). For serum samples, IgG responses to gB were the strongest with 20 positive samples (83.3% 
positive) whereas the IgA responses were much more variable and titrated out earlier than IgG 
although 19 samples (79.16%) remained positive at 1:100 dilution (Fig 1A). Serum IgG and IgA 
responses to AD-2 were generally weaker than those to gB, with 16 samples IgG positive (66.66%) but 
only 4 samples determined as IgA positive at 1:100 dilution (20.8%) (Fig 1A). In general, the saliva 
results (Fig. 1B) display similar trends as those observed with serum (Fig. 1A)match those observed 
with serum (Fig. 1A). For gB, binding of IgA was significantly weaker than IgG and for AD-2 a reduced 
frequency of positive samples was noted. 
Representation of these data as scatterplot correlations allowed us to compare individual IgG and IgA 
responses to gB and AD-2 together (Fig 2). The strongest correlations were observed with serum and 
saliva IgG responses with maximal rR2 values of 0.56562721 and 0.74332899 respectively (Fig 2A). 
Correlations were lower for both serum and saliva IgA responses but saliva IgA responses showed 
similar trends as found with serum (Fig 2B). These data most likely reflect the differences in relative 
levels of each Ab isotype between saliva and serum, with serum containing excess IgG over IgA and 
saliva more balanced levels [39]. These data are also consistent with AD-2 responses being extremely 
variable between individuals whereas gB responses are reliably stronger, reflecting the number of 
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possibilities that polyclonal Abs have to bind the much larger gB molecule with its additional available 
epitopes. Thus, only a proportion of individuals generate IgG and IgA to the AD-2 epitope despite being 
considered HCMV seropositive. 
IgG and IgA responses to HCMV gB and AD-2 in recombinant gB vaccine recipients
To compare natural infection with vaccination, we investigated human serum samples obtained from 
a prior vaccine trial of recombinant gB from HCMV [32] for IgG and IgA responses to HCMV gB and the 
AD-2 epitope. Findings for IgG responses had been previously published [35] and demonstrated that 
levels of IgG to AD-2 correlated with a reduced incidence of viremia in HCMV seropositive transplant 
recipients. Importantly, whilst the gB vaccine could boost pre-existing IgG responses against AD-2, de 
novo IgG responses were not detected [27]. We therefore decided to investigate whether these data 
with IgG were reflected with the IgA isotype response. Figure 3 displays our findings investigating 
serum IgG and IgA responses to gB and the AD-2 epitope for placebo and vaccine recipients, stratified 
by HCMV-seropositive status. The gB/MF59 vaccine boosted gB binding Abs in seropositive recipients 
particularly only in the IgA responses which reached statistical significance (Fig 3A). IgG and IgA 
responses to AD-2 were similarly boostedshowed a trend towards boosting (Fig 3A) but did not reach 
statistical significance. However, if individuals were stratified into AD-2 responders (based on one 
sample being considered positive according to cut off values) and removed the AD-2 non-responders 
(no positive AD-2 sample) the vaccine clearly boosted pre-existing AD-2 responses (Supplementary 
Figure 2). Thus, AD-2 responses do not develop in all subjects and gB vaccination can boost these 
responses only in seropositive subjects that have already developed AD-2 responses after natural 
infection. In seronegative gB vaccine recipients, robust IgG and mixed but significantvariable IgA 
responses to gB were also detected. However, consistent with previous studies, IgG responses to the 
linear AD-2 epitope were not induced by vaccine and. Furthermore, similar results were obtained with 
IgA (Fig 3B). Therefore, vaccination with gB does not elicit de novo AD-2 responses in seronegative or 
seropositive subjects. In conclusion, theseThus, the new findings assessing IgA responses in response 
to gB/MF59 match those previously found for IgG [35]. Finally, analysis of individuals’ responses 
revealed that all the IgA positive samples to AD-2 were also IgG positive. 
Human milk IgG and IgA display different binding profiles to gB and AD-2
Thus far we could detect IgA responses against both gB and AD-2 in natural infection and that 
vaccination promoted IgA responses against gB. The studies in both sera and saliva also suggested that 
the IgG response predominated over IgA, and thereforeso we next turned our attention to human 
antibody responses to HCMV found in breast milk samples. Similarly, to human serum and saliva 
samples, we determined binding responses to gB and AD-2 with data presented as dot plots and 
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correlations in Figure 4. Fourteen samples were investigated. Again, we used 4 seronegative breast 
milk samples to determine positive negative cut-off values for the ELISA (Supplementary Figure 3). For 
the remaining 10 samples we observed similar binding profiles of IgG and IgA to gB that titrated out 
quickly at 1:500 (Fig 4A). Interestingly, for AD-2 binding, we found that IgA responses were significantly 
stronger than IgG (Fig 4A) in contrast to that observed with serum and saliva. The scatterplot 
correlations comparing individual samples binding response to gB and AD-2 confirmed these data and 
demonstrated that the best (rR2 = 0.56373265) is seen with IgA responses (Fig 4B). Thus, the IgG/IgA 
picture in breast milk was clearly different to that seen in saliva and sera. 
Light chain usage by serum antibodies binding gB and AD-2
Following the characterisation of isotype responses in multiple compartments we next sought to 
investigate the biology of AD-2 antibodies in more detail. First, we characterised the contribution of 
the light chains to these antibodies found in human serum. We found that antibodies binding to gB 
displayed a balanced usage of kappa () and lambda () light chains whereas the antibodies binding 
to AD-2 were restricted to  chain usage (Fig 5A). These data are confirmed within the scatterplot 
correlations comparing individual responses to gB and AD-2 where the use of  light chains displays 
rR2 values ranging from 0.52342647 to 0.58042973 whereas  light chain usage does not display 
significant values (Fig 5B). Similar results were observed when testing human milk samples for light 
chain usage in antibodies binding to gB and AD-2 (Supplementary Figure 4), suggesting that both IgG 
and IgA binding to AD-2 prefers the use of  chains. 
AD-2 specific recombinant antibodies expressed as IgG1 and IgA1
Using this information we next expressed three human recombinant antibodies specific for AD-2 [22] 
as both human IgG1 and IgA1 using immunoglobulin expression vectors (pHC-huC1, pHC-huC1) and 
mammalian cell expression systems [38]. Our data from Figure 5 and previous V region sequencing 
analyses [22] demonstrated that all Abs binding AD-2 used  Light chains and therefore we could 
construct intact V region matched human Abs by co-expression with pLC-huC expression vectors. 
Figure 6 displays expression and binding data for recombinant immunoglobulins 8F9, QG1 and FA9. 
We first expressed these antibodies as both IgG1 and IgA1 and measured levels in culture 
supernatants and compared IgG1 and IgA1 binding to both gB and AD-2. All were effectively expressed 
and bound to gB and AD-2 as both IgG1 and IgA1 except for clone FA9 IgA1 (Fig 6A). We therefore 
decided to focus further studies on 8F9 and QG1 clones and normalise their concentrations as IgG1 
and IgA1. These analyses revealed significantly stronger binding of IgG1 to both gB and AD-2 as 
compared to IgA1 (Fig 6B). These data confirm that V region matched recombinant Abs show constant 
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region dependent binding differences with IgG1 consistently stronger than IgA1, particularly when 
analysing binding to AD-2.
Recombinant IgG1 and IgA1 binding to cell-associated gB and neutralization of HCMV in vitro
To confirm the data observed in ELISA binding experiments we performed investigations using cells 
engineered to express an N-terminal fragment of gB [22] and compared AD-2 specific recombinant 
IgG and IgA binding. These experiments were designed to mimic what might be expected to occur for 
recognition via the AD-2 epitope of cell-associated gB via the AD-2 epitope. Figure 7A and 
Supplementary Figure 5 displays the flow cytometric analysis of recombinant IgG1 and IgA1 binding 
to cells expressing a fragment of gB. BSignificant binding of the 8F9 and QG1 clones expressed as IgG1 
was observed but very limited binding was detected when using the V region matched IgA1 variants. 
These data confirm that seen in ELISA experiments (Fig 6B) where reduced binding of the IgA1 clones 
to AD-2 was noted. Despite the apparent reduced IgA1 binding to AD-2, surprisingly, we found that 
the IgA1 was still able to neutralise HCMV infection in vitro (Fig 7B). In particular, 8F9 IgA1 neutralised 
at lower concentrations than 8F9 IgG1 (IC50 0.2g/ml vs 1g/ml) and completely neutralised at 
2g/ml. In contrast, QG1 IgA1 was less effective compared to its IgG1 counterpart (IC50 3g/ml vs 
0.8g/ml) and was unable to completely neutralise HCMV. Importantly, IgA1 antibodies 8F9 and QG1 
also neutralised HCMV infection of epithelial cells (Fig 7C). These results suggest that the structural 
form of the AD-2 epitope (within recombinant gB, synthetic peptide, cell-surface expression, native 
virion) can influence recognition by Abs and in particular, IgG versus IgA.
Discussion
In this study, through a comparison of human IgG and IgA responses to HCMV gB and AD-2 epitope 
found in serum, saliva and breast milk, we have investigated a potential role for IgA antibodies against 
HCMV infection. Despite relatively weak IgA responses and reduced frequency of binding to AD-2 in 
matched human serum and saliva samples, we detected strong binding of IgA from breast milk and 
recombinant IgA1 to AD-2 bound effectively to both gB and AD-2 and neutralized HCMV in vitro. 
Interestingly we found that gB/MF59 vaccination boosted both IgG and IgA binding to gB and AD-2 
but only with pre-existing responses for the latter. Our data are supportive of an important role for 
human IgA to gB and AD-2 in the protective immune response against HCMV and warrant further 
investigation in gB vaccine trials.
Recombinant HCMV gB is under evaluation as a subunit vaccine to protect against congenital HCMV 
infection and transplant-related viremia. Serum Abs obtained from one such vaccine trial [32] were 
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used to probe the IgA responses to gB and AD-2 epitope following gB/MF59 vaccination. Our results 
with IgA responses are consistent with those previously reported for IgG [35] with vaccination inducing 
de novo IgA responses to gB  in seronegative recipients and boosting IgA responses in seropositive 
recipients. In fact, gB vaccination reliably and significantly induced serum IgA responses to gB in both 
seropositive and seronegative recipients suggesting that this component of the HCMV immune 
response is induced via the vaccine regimen. Prior analyses of epitope specific gB IgG responses in 
vaccine recipientsthis transplant cohort revealed that AD-2 Abs were linked with reduced viremia and 
suggested that this might be a correlate of protection in HCMV seropositive solid organ transplant 
recipients transplantation patients [35]. Importantly, vaccination with gB boosted these pre-existing 
IgG AD-2 responses but failed to induce de novo responses. We now show that this boosting effect 
also occurred in those individuals with pre-existing IgA to AD-2. The key question is whether IgA 
responses against AD2 are protective – however, given the number of patients with IgA AD-2 
responses it was not possible to perform a retrospective clinical analysis of outcome. However, our in 
vitro neutralisation data argue that IgA responses against AD-2 could be protective. Thus, we propose 
that future studies of the humoral response to gB should include IgA analyses particularly in ongoing 
vaccine studies particularly those proposing to use AD-2 as the immunogen. 
Our data are consistent with previous studies that have shown that IgG Abs to AD-2 in humans are 
known to be composed of a restricted set of Vh and V regions [22, 40] which could be one reason 
why such Abs are rare and outnumbered by Abs binding other gB epitopes [21]. This feature of AD-2 
Abs of both the IgG and IgA isotypes can also explain the low frequency of de novo synthesis of AD-2 
Abs following gB vaccination. Our current investigations have revealed new structural constraints of 
Abs binding to AD-2. Here, we demonstrated that light chain usage in AD-2 specific Abs is restricted 
to use of  light chains whereas Abs binding to other epitopes of gB can consist of either  or  light 
chains. This feature of Abs binding short linear peptides is not unique to AD-2 and has been 
demonstrated previously, with the preferential use of  L-chains a reflection of limited antigenic 
complexity [24]. This could indicate another immune evasion mechanism of HCMV to restrict immune 
responses to an important conserved epitope required by the virus for cell entry.
To confirm our data with polyclonal Abs and to establish the significance of IgA to AD-2, we created 
three V region matched AD-2 specific mAbs as both IgG1 and IgA1. Our results with these mAbs 
demonstrated that even though IgG1 binding was stronger towards synthetic AD-2 peptide, 
membrane associated AD-2 epitope and recombinant gB, as compared to IgA1 binding, we found that 
IgA1 binding AD-2 could efficiently neutralize HCMV in vitro. Thus, crucially, the IgA antibodies were 
clearly functional against HCMV. It is difficult to determine the contribution of IgA within polyclonal 
preparations where competition between IgG and IgA might be expected, therefore our mAb studies 
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are important to establish the relative importance of IgA responses to HCMV. Our data may reflect 
the natural binding preferences among the different Ab isotypes including C region effects on affinity 
and avidity for antigens observed previously [41]. Most importantly our data demonstrate that IgA is 
capable of binding to AD-2, particularly in the absence of IgG, and strengthen our observations that 
IgA in human breast milk displays superior binding over IgG.
It is important that human IgA binding AD-2 was capable of neutralizing HCMV in vitro. In fact, the 
best neutralizing recombinant clone was 8F9 expressed as human IgA1. It displayed improved 
neutralizing capabilities over its IgG1 counterpart, requiring lower concentrations to achieve 
significant neutralization effects. Surprisingly, this particular Ab clone did not display significant 
binding to AD-2 in various assays, demonstrating the complexity of interpreting these data where 
antigens in different bioanalytical formats are used. Nevertheless, these data verify that the AD-2 
epitope can be targeted for the development of highly efficient mAbs for HCMV treatment and 
support recent studies investigating this potential. The AD-2 specific mAb TRL345, which has produced 
promising preclinical results including the potential for preventing congenital transmission [42, 43]. 
Another AD-2 binding mAb, TCN-202 has undergone phase 1 clinical trial and proved to be well 
tolerated but further trials have not yet proceeded. The 8F9 mAb described here and previously [22] 
is also a prototype biotherapeutic that will be investigated in further studies.
Our experiments also used matched human serum and saliva samples to compare the Abs for binding 
to gB and AD-2 epitope. Similarly, to the gB vaccine study, a major observation was the much weaker 
IgA response to gB and AD-2 epitope when compared to IgG responses. This occurred in both serum 
and saliva samples, in fact serum results were generally indistinguishable from those found with saliva. 
This is somewhat surprising when considering that normal serum IgG levels are significantly higher 
than IgA whereas in saliva, the opposite is true and less competition from IgG would be expected. 
Nevertheless, our results confirm that IgG is the dominant isotype of Abs to gB and AD-2 in both serum 
and saliva from healthy individuals naturally exposed to HCMV. These data are in agreement with 
another study showing sensitive and specific detection of IgG to gB in saliva [44]. Conversely, we found 
that human breast milk Abs binding AD-2 were largely of the IgA isotype whilst a balanced IgG and IgA 
response was observed to gB. In fact, we observed IgA AD-2 responses in 90% of positive human breast 
milk samples as opposed to much reduced frequency of IgG responses. These data may reflect the 
different structural properties of IgA that exists as a monomer in serum, as does IgG, and dimeric or 
polymeric mucosal secretory IgA that is predominantly found in breast milk [45].  Thus, differences in 
the relative concentration and structure of IgG and IgA between serum, saliva and breast milk may 
account for their variable binding affinity to AD-2. More generally, this preponderance of IgA 
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antibodies against HCMV in breast milk may be an important component of passive immunity 
transferred between mother and child.
An additional important observation in the study was that all HCMV seropositive individuals (defined 
as producing IgG to gB), did not necessarily produce IgG or IgA to AD-2. In fact, samples that contained 
IgG to gB displayed variable AD-2 binding with a reduced proportion of those considered positive. 
These data are in agreement with previous studies that have shown approximately 50% of individuals 
produce antibodies to AD-2 [46, 47]. It is speculated that AD-2 binding Abs are restricted in nature due 
to limited structural constraints allowing antigen recognition [21, 48]. This phenomenon can also help 
explain the reduced frequency and ability of serum and salivary IgA to bind AD-2. In fact, we observed 
true IgA AD-2 response in only one saliva sample and just four serum samples out of a total of twenty. 
However, human breast milk studies indicated a dominant IgA response to AD-2 epitope as compared 
to IgG in seropositive individuals. 
We have demonstrated in breast milk significant human IgA responses to AD-2, an important 
neutralizing epitope of HCMV, and determined that IgA binding is capable of neutralizing HCMV in 
vitro. This may indicate a function for neonatal protection against HCMV conferred by IgA binding AD-
2. Studies using saliva and serum samples, including those obtained from a recombinant gB vaccine 
trial, displayed much weaker IgA binding to AD-2 which we conclude is due to competition with the 
higher IgG levels present. In seronegative gB vaccine recipients, we could not detect IgA or IgG to AD-2, 
despite the generation of both IgA and IgG to gB with this vaccination regimen, demonstrating the 
immunodominance of other gB epitopes. The protective immune response to HCMV is clearly very 
complex, requiring both cellular and humoral immunity [49]. It is also well known that Ab responses 
to the AD-2 epitope of gB are extremely variable and inconsistent. We report that IgA to AD-2 is, 
numerically, a minor component of HCMV humoral immunity but is protective and warrants further 
investigation, in particular with respect to induction via vaccination strategies. The AD-2 epitope can 
also be targeted for the development of potent therapeutic mAbs as an effective treatment option for 
HCMV, including those of the IgA isotype. Targeted Ab cocktails consisting of several Abs with different 
specificities and properties may therefore find utility in HCMV treatment. 
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Figure Legends
Figure 1. Human IgG and IgA bind HCMV gB and AD-2. 
ELISA to determine IgG and IgA binding to gB and AD-2 epitope of HCMV in (A) human serum (n=24) 
and (B) human saliva (n=24). All samples were diluted as indicated and data is represented as 
OD450nm values of triplicate determinations of three independent experiments. Horizontal dotted 
lines representing positive/negative cut off values for negative gB and negative AD-2 samples were 
based on IgG gB negative samples (n=4).  Statistical differences comparing the mean OD450nm values 
of IgG and IgA binding to gB and AD-2 epitope at each dilution was obtained by Mann-Whitney test 
(ns, not significant; **** P < 0.0001).
Figure 2. Scatterplot correlations of individual samples displaying IgG and IgA binding to both HCMV 
gB and the AD-2 epitope. 
ELISA data displaying comparative IgG (A) and IgA (B) binding to gB and AD-2 epitope of HCMV in each 
sample of human serum (n=24) and human saliva (n=24). Samples were diluted as indicated and data 
is represented as OD450nm values of triplicate determinations of three independent experiments. 
Horizontal  and vertical dotted lines representing positive/negative cut off values for negative gB and 
negative AD-2 samples respectively were based on IgG gB negative samples (n=4). Correlation 
coefficients (Spearman’s) and statistical significance for each set of determinations comparing serum 
or saliva  IgG and IgA binding to gB and AD-2 epitope are displayed within each graph.
Figure 3. gB vaccination induces IgG and IgA responses to gB and AD-2 in seropositive recipients.
Serum samples obtained from the recombinant gB vaccination trial were analysed for IgG and IgA 
binding to gB and AD-2 by ELISA. Individuals were stratified into (A) seropositive (IgG+ to gB) and (B) 
seronegative (IgG- to gB). Statistical differences between the mean OD values of day 0 and day 56 of 
vaccine recipients for IgG and IgA for binding to gB and AD-2 epitope was obtained from Mann-
Whitney test (ns, not significant; * P < 0.05; **** P < 0.0001). Placebo groups showed no significant 
differences.
Figure 4. Human milk-derived IgG and IgA bind HCMV gB and AD-2. 
(A) ELISA to determine IgG and IgA binding to gB and AD-2 epitope of HCMV in human breast milk 
samples (n=14). Samples were diluted as indicated and data is represented as OD450nm values of 
triplicate determinations of three independent experiments. Horizontal dotted lines representing 
positive/negative cut off values for negative gB and negative AD-2 samples were based on IgG gB 
negative samples (n=4). Statistical differences comparing the mean OD450nm values of IgG and IgA 
binding to gB and AD-2 epitope at each dilution in part A was obtained by Mann-Whitney test (ns, not 
significant; ** P < 0.01; *** P < 0.001). (B) Scatterplot correlations of individual undiluted samples 
displaying IgG and IgA binding to both HCMV gB and the AD-2 epitope. Horizontal  and vertical dotted 
lines are shown representing positive/negative cut off values for negative gB and negative AD-2 
samples respectively and were based on IgG gB negative samples (n=4). Correlation coefficients 
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(Spearman’s) and statistical significance for each set of determinations comparing IgG or IgA binding 
to gB and AD-2 epitope are displayed within each graph. 
Figure 5. Human antibodies binding HCMV AD-2 epitope preferentially use kappa () light chains.
(A) ELISA to determine light chain usage of Ig’s binding to gB and AD-2 epitope of HCMV human serum 
(n=24). Horizontal dotted lines representing positive/negative cut off values for negative gB and 
negative AD-2 samples were based on the IgG gB negative samples (n=4). Statistical differences 
comparing the mean OD450nm values for kappa () and lambda () chain use at each dilution was 
obtained by Mann-Whitney test (ns, not significant; **** P < 0.0001). (B) ELISA data displaying 
comparative  and  usage in Ig’s binding to gB and AD-2 epitope of HCMV in serum samples. 
Horizontal  and vertical and dotted lines representing positive/negative cut off values for negative gB 
and negative AD-2 samples respectively were based on the IgG gB negative samples (n=4). Correlation 
coefficients (Spearman’s) and statistical significance for each set of determinations comparing  or  
usage in Ig’s binding to gB and AD-2 epitope are displayed above each graph.
Figure 6. Recombinant  antibodies expressed as human IgG and IgA bind gB and AD-2 epitope of 
HCMV. 
(A) Expression of  monoclonal recombinant antibodies QG1 IgG1, QG1 IgA1, 8F9 IgG1, 8F9 IgA1, FA9 
IgG1 and FA9 IgA1 by transient transfection and ELISA of undiluted culture supernatants and binding 
to gB and AD-2. +ve control diluted human serum, –ve control undiluted culture supernatant from 
untransfected cells, unrelated IgG and IgA are control human mAbs. (B) Binding and titration of 
concentration-matched mAbs QG1 IgG1 (black bars), QG1 IgA1 (grey bars), 8F9 IgG1 (black bars), 8F9 
IgA1 (grey bars), FA9G and FA9A to gB and AD-2 epitope of HCMV represented as OD values with 
human serum as positive control and unrelated IgG and unrelated IgA as negative control. Statistical 
differences between the mean OD values of IgG and IgA expression and for binding to gB and AD-2 
epitope was obtained from Mann-Whitney test ( ** P < 0.01; **** P < 0.0001).
Figure 7. AD-2 specific IgA mAbs neutralize HCMV in vitro.
(A) Isotype matched mAbs 8F9 (IgG1 and IgA1) and QG1 (IgG1 and IgA1) binding to NS0 cells 
engineered to express the N-terminal fragment of gB (NS0-gBNT) as measured by flow cytometry. 
Grey filled histogram secondary Ab alone, mAb 2g/ml (black line), 1g/ml (dark grey line), 0.2g/ml 
(light grey line) (B) Neutralisation assays for HCMV infection of human foreskin fibroblasts (HFFs) 
represented as percentage of cells infected cellswith high passage Merlin strain of HCMV. 8F9 IgG1, 
8F9 IgA1, QG1 IgG1 and QG1 IgA1 were titrated with data shown as representative of 2 independently 
performed experiments. (C) Neutralisation assay for HCMV (TB40/e) infection of human epithelial cells 
(ARPE-19) represented as infection relative to no Ab control (assigned 1.0). 8F9 IgA1 and QG1 IgA1 
were diluted 1:3 and assayed in triplicate. Statistical differences between the mean values of each 
mAb compared to no mAb for each concentration was obtained by Mann-Whitney test (no asterisk is 
not significant; * P < 0.05; ** P < 0.01; P < 0.001). 
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Supplementary 
Figure 1
 
SFig 1: Cut off graphs of four human serum samples determined to be negative at 1:100 dilution for IgG to gB, IgA to gB, IgG to AD-2 
and IgA to AD-2. Cut offs were calculated at each dilution based on the 2 standard deviations above the mean of all the OD values 
obtained from replicate assays of all 4 samples. Tables demonstrate cut off values obtained for all samples at each dilution for the 
same 4 samples in various assays.
Serum IgG gB IgA gB IgG AD-2 IgA AD-2
1:100 0.116 0.096 0.150 0.207
1:500 0.089 0.055 0.143 0.107
1:1000 0.143 0.034 0.179 0.074
Saliva IgG gB IgA gB IgG AD-2 IgA AD-2
1:2 0.059 0.056 0.072 0.039
1:4 0.040 0.037 0.072 0.026
1:8 0.022 0.019 0.018 0.008
k/l IgG gB IgA gB IgG AD-2 IgA AD-2
1:100 0.078 0.053 0.098 0.033
1:500 0.056 0.022 0.096 0.045
1:1000 0.048 0.000 0.057 0.032
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SFig 2. Serum  samples  from  seropositive  recipients  of  the 
recombinant  gB  vaccination  trial  were  analysed  for  IgG  and  IgA 
binding  to  AD-2  by  ELISA.  Only  individuals  where  one  sample  is 
considered positive (according to cut off values obtained in SFig 1) 
are  shown. Statistical differences  between  the mean OD values of 
day 0 and day 56 of placebo and vaccine recipients for IgG and IgA 
for binding to AD-2 epitope were obtained from Mann-Whitney test 
(ns, not significant; * P < 0.05). Placebo groups  for  IgA  showed no 
positive samples and are not included.
 
Supplementary Figure 2
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Supplementary figure 3
 
S Fig 3: Cut off graphs of four undiluted human breast milk samples determined to be negative for IgG to gB, IgA to gB, IgG to AD-2 
and IgA to AD-2. Cut off values are determined as the mean +2SD of all 4 samples. The table displays all cut off values obtained at 
the various dilutions of breast milk.
Milk IgG gB IgA gB IgG AD-2 IgA AD-2
undiluted 0.209 0.312 0.163 0.388
1:50 0.114 0.061 0.053 0.103
1:500 0.062 0.042 0.074 0.056
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Supplementary figure 4
S Fig 4A: Usage of kappa () and lambda () L-chains
by undiluted human milk antibodies binding to gB and
AD-2 epitope. Statistical differences between the
mean OD values of antibodies containing the
indicated L-chains for binding to gB and AD-2 epitope
was obtained by Mann-Whitney test (**** P < .0001).
S Fig 4B: Correlations of kappa () and lambda () L-
chains usage by human milk antibodies binding to
gB and AD-2 epitope. Vertical (AD-2) and horizontal
(gB) dotted lines represent cut offs for negative
kappa and negative lambda samples respectively.
Spearman’s correlations and p values are shown.
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Supplementary 
figure 5 
SFig 5A: Cells profile SSC v FSC and gate 
application (black box) of unstained NS0 cells 
(upper) and NS0 cells expressing gB-NT (lower).
SFig 5B: Cell surface expression of gB-NT.
Binding of human recombinant monoclonal antibody 8F9 IgG 
to parental NS0 cells (upper) and NS0 cells expressing gB-NT 
(lower). Black line represents unstained cells, red represents 
fluorescence of cells stained with secondary Ab alone (anti-
human kappa FITC) and blue represents cells stained with 
8F9 IgG and secondary Ab. 
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